To Evaluate the Efficacy and Tolerability of Sodium Bicarbonate Toothpaste

GlaxoSmithKline (GSK)

Status and phase

Completed

Phase 2

Conditions

Oral Hygiene

Treatments

Drug: Sodium fluoride

Drug: Sodium bicarbonate plus sodium fluoride

Study type

Interventional

Funder types

Industry

Identifiers

NCT02207907

RH02433 (Other Identifier)

202192

Details and patient eligibility

About

The primary objectives of this study will be to compare the Gingival Bleeding and Gingival Inflammation following twice daily use of a sodium bicarbonate experimental dentifrice compared to a 0% sodium bicarbonate toothpaste after 24 weeks of use. The study will be conducted at Silverstone Research Group. Participants will be recruited from their database and by use of an external recruitment agency.

Enrollment

247 patients

Sex

All

Ages

18 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Good general health with (in the opinion of the investigator) no clinically significant and relevant abnormalities of medical history or oral/dental examination.
A minimum of 20 permanent gradable teeth
Moderate gingivitis present at the screening visit in the opinion of the investigator
A total of 20 bleeding sites or greater at baseline visit
Positive response to bleeding on brushing present at the screening visit

Exclusion criteria

Pregnant or breast feeding women
Tobacco chewers
Current or relevant history of any serious, severe or unstable physical or psychiatric illness or any other medical condition (e.g. Diabetes Mellitus) that would make the participant unlikely to fully complete the study or any that increases the risk to the participants or undermines the data validity.
Recent history (within the last year) of alcohol or other substance abuse
Participants requiring prophylactic antibiotic treatment prior to dental therapy
Known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients
Have current active caries or any medical conditions which may directly influence gingival bleeding
Use of concomitant or any systemic medication that, in the opinion of the investigator, might interfere with the outcome of the study or have an effect on gingival conditions within 14 days of gingival examinations
Excessive calculus present that interferes with the probing examination for Gingival Bleeding Index
Participation in another clinical study or receipt of an investigational drug or oral care product within 30 days of the screening visit
An employee of the sponsor or the study site or members or their immediate family.